Original article

Clinical and genetic characteristics of Kallmann syndrome

  • Yijun TANG ,
  • Qianwen ZHANG ,
  • Yirou WANG ,
  • Yao CHEN ,
  • Xin LI ,
  • Juan LI ,
  • Jian WANG ,
  • Xiumin WANG
Expand
  • 1. Department of Endocrinology and Metabolism, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2. Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Received date: 2022-08-01

  Online published: 2023-07-05

Abstract

Objective To analyze the clinical and genotypic characteristics of children with Kallmann syndrome (KS), and to strengthen clinicians' understanding of the disease. Methods The clinical characteristics, whole-exome gene sequencing results, and treatment outcomes of 20 KS patients were retrospectively analyzed. Results Among the 20 patients, 17 were boys and 3 were girls. The mean age at diagnosis was 13.13 years old. Male children presented micropenis with small testicular size and history of bilateral cryptorchidism, while female patients presented primary amenorrhea and retardation of breast development. The results of Chinese odor recognition test indicated that 93.75% (15/16) children had olfactory disorder. Children with KS may have other systemic manifestations, including neurodevelopmental delay, mental retardation, phalangeal abnormalities, hearing impairment, and congenital cleft lip and palate. Among the 19 patients who underwent whole-exome gene sequencing, 12 variation sites in 6 genes were found, including FGFR1, CHD7, SOX10, KAL1, PROKR2 and SOX2. The molecular diagnosis rate was 63.16% (12/19). Testicular size, penile length, penile girth, T, LH and FSH were significantly improved after receiving pulsatile GnRH pump treatment, and there were no obvious adverse reactions. Conclusions The application of Chinese odor recognition tests can more accurately evaluate olfactory function in children with KS. The whole-exome gene sequencing technology is helpful to improve the molecular diagnosis of the disease, so as to diagnose the children with this rare disease as early as possible. Pulsatile GnRH pump therapy promotes sexual development in children with KS without obvious adverse effects.

Cite this article

Yijun TANG , Qianwen ZHANG , Yirou WANG , Yao CHEN , Xin LI , Juan LI , Jian WANG , Xiumin WANG . Clinical and genetic characteristics of Kallmann syndrome[J]. Journal of Clinical Pediatrics, 2023 , 41(7) : 537 -542 . DOI: 10.12372/jcp.2023.22e1053

References

[1] 中华医学会内分泌学分会性腺学组. 特发性低促性腺激素性性腺功能减退症诊治专家共识[J]. 中华内科杂志, 2015, 54(8): 739-744.
[2] Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypo-gonadism[J]. Metabolism, 2018, 86: 124-134.
[3] Ono M, Harley VR. Disorders of sex development: new genes, new concepts[J]. Nat Rev Endocrinol, 2013, 9(2): 79-91.
[4] Wang Y, Qin M, Fan L, et al. Correlation analysis of genotypes and phenotypes in Chinese male pediatric patients with congenital hypogonadotropic hypogonadism[J]. Front Endocrinol (Lausanne), 2022, 13: 846801.
[5] Young J. Exome sequencing as a tool for detecting point mutations and deletions in patients with hypogonadotropic hypogonadism[J]. J Clin Endocrinol Metab, 2022, 107(10): e4254-e4255.
[6] Feng G, Zhuang Y, Yao F, et al. Development of the Chinese smell identification test[J]. Chem Senses, 2019, 44(3): 189-195.
[7] Wu X, Geng Z, Zhou S, et al. Brain structural correlates of odor identification in mild cognitive impairment and Alzheimer's disease revealed by magnetic resonance imaging and a Chinese olfactory identification test[J]. Front Neurosci, 2019, 13: 842.
[8] Zhang Q, Ding Y, Feng B, et al. Molecular and phenotypic expansion of Alstr?m syndrome in Chinese patients[J]. Front Genet, 2022, 13: 808919.
[9] Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol, 2015, 11(9): 547-564.
[10] 中华医学会男科学分会, 下丘脑促性腺激素释放激素脉冲泵在男科疾病中应用专家共识编写组. 下丘脑促性腺激素释放激素脉冲泵在男科疾病中应用专家共识[J]. 中华男科学杂志, 2022, 28(3): 273-280.
[11] Ottaviano G, Cantone E, D'Errico A, et al. Sniffin' Sticks and olfactory system imaging in patients with Kallmann syndrome[J]. Int Forum Allergy Rhinol, 2015, 5(9): 855-861.
[12] Sato N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients[J]. J Clin Endocrinol Metab, 2004, 89(3): 1079-1088.
[13] Xu C, Cassatella D, van der Sloot AM, et al. Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants[J]. Genet Med, 2018, 20(8): 872-881.
[14] 中华医学会儿科学分会内分泌遗传代谢学组. 性发育异常的儿科内分泌诊断与治疗共识[J]. 中华儿科杂志, 2019, 57(6): 410-418.
[15] 王浩, 乔洁. 新一代测序技术在性发育异常疾病诊断中的应用[J]. 中华内分泌代谢杂志, 2018, 34(11): 963-967.
[16] 林胡, 杨浩, 傅君芬, 等. 中国性发育异常患儿临床表型与基因型分析[J]. 中华儿科杂志, 2022, 60(5): 435-441.
[17] Stamou MI, Brand H, Wang M, et al. Prevalence and phenotypic effects of copy number variants in isolated hypogonadotropic hypogonadism[J]. J Clin Endocrinol Metab, 2022, 107(8): 2228-2242.
[18] Shima H, Ishii A, Wada Y, et al. SOX2 nonsense mutation in a patient clinically diagnosed with non-syndromic hypogonadotropic hypogonadism[J]. Endocr J, 2017, 64(8): 813-817.
[19] Panaliappan TK, Wittmann W, Jidigam VK, et al. Sox2 is required for olfactory pit formation and olfactory neurogenesis through BMP restriction and Hes5 upregulation[J]. Development, 2018, 145(2): dev153791.
[20] Dvorakova M, Macova I, Bohuslavova R, et al. Early ear neuronal development, but not olfactory or lens development, can proceed without SOX2[J]. Dev Biol, 2020, 457(1): 43-56.
[21] Nordenstr?m A, Ahmed SF, van den Akker E, et al. Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline[J]. Eur J Endocrinol, 2022, 186(6): G9-G49.
[22] Gong C, Liu Y, Qin M, et al. Pulsatile GnRH is superior to hCG in therapeutic efficacy in adolescent boys with hypogonadotropic hypogonadism[J]. J Clin Endocrinol Metab, 2015, 100(7): 2793-2799.
[23] Wei C, Long G, Zhang Y, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis[J]. World J Mens Health, 2021, 39(4): 654-665.
Outlines

/